0000905718-20-000470.txt : 20200519 0000905718-20-000470.hdr.sgml : 20200519 20200519202632 ACCESSION NUMBER: 0000905718-20-000470 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200515 FILED AS OF DATE: 20200519 DATE AS OF CHANGE: 20200519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Park West Asset Management LLC CENTRAL INDEX KEY: 0001386928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36351 FILM NUMBER: 20895424 BUSINESS ADDRESS: STREET 1: 900 LARKSPUR LANDING CIRCLE, SUITE 165 CITY: LARKSPUR STATE: CA ZIP: 94939 BUSINESS PHONE: (415) 524-2902 MAIL ADDRESS: STREET 1: 900 LARKSPUR LANDING CIRCLE, SUITE 165 CITY: LARKSPUR STATE: CA ZIP: 94939 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLx Pharma Inc. CENTRAL INDEX KEY: 0001497504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271707962 STATE OF INCORPORATION: DE FISCAL YEAR END: 0515 BUSINESS ADDRESS: STREET 1: 9 FISHERS LANE STREET 2: SUITE E CITY: SPARTA STATE: NJ ZIP: 07871 BUSINESS PHONE: (713) 842-1249 MAIL ADDRESS: STREET 1: 9 FISHERS LANE STREET 2: SUITE E CITY: SPARTA STATE: NJ ZIP: 07871 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20140313 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, LLC DATE OF NAME CHANGE: 20100726 4 1 plxpharma_fm4may152020.xml X0306 4 2020-05-15 0 0001497504 PLx Pharma Inc. PLXP 0001386928 Park West Asset Management LLC 900 LARKSPUR LANDING CIRCLE, SUITE 165 LARKSPUR CA 94939 0 0 1 0 Series B Convertible Preferred Stock 3.10 2020-05-15 4 P 0 6000 1000 A 2020-05-15 Common Stock 1935483 6000 I See Footnotes Park West Asset Management LLC (the "Reporting Person") is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company ("PWIMF"), and Park West Partners International, Limited, a Cayman Islands exempted company ("PWPI" and, together with PWIMF, the "PW Funds"). Peter S. Park ("Mr. Park") is the sole member and manager of the Reporting Person. Each share of Series B Convertible Preferred Stock, par value $0.001 per share ("Series B Preferred Stock"), of PLx Pharma Inc. (the "Company") is convertible at any time into a number of shares of common stock, par value $0.001 ("Common Stock"), of the Company equal to the stated value (initially $1,000) divided by the conversion price (initially $3.10), in each case subject to customary adjustments under the certificate of designations for the Series B Preferred Stock (the "Certificate of Designations"). Unless converted pursuant to its terms, the Series B Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion. As of May 15, 2020, PWIMF held 5,450 shares of Series B Preferred Stock and PWPI held 550 shares of Series B Preferred Stock. The Reporting Person's and Mr. Park's beneficial ownership is limited to their pecuniary interest, if any, in such securities. /s/ Grace Jimenez, Chief Financial Officer of Park West Asset Management LLC 2020-05-19